Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
A first-in-human, phase I trial explored the safety and preliminary efficacy of the CDK9 inhibitor KB-0742 in patients with advanced, transcription factor-dependent solid tumors including ACC. KB-0742 was well tolerated with evidence of disease stabilization observed among some patients with ACC, but overall therapeutic efficacy was limited.
Authors
- Luis A. Carvajal (ORCID: https://orcid.org/0009-0004-0517-0727)
- Elizabeth Olek (ORCID: https://orcid.org/0000-0003-4128-249X)
- Miguel A. Villalona‐Calero (ORCID: https://orcid.org/0000-0002-1991-5070)
- Rashmi K Chugh (ORCID: https://orcid.org/0000-0002-4633-6971)
- Jacob Thomas (ORCID: https://orcid.org/0000-0002-8420-366X)
- Glenn J. Hanna (ORCID: https://orcid.org/0000-0002-9969-2523)
- Jyoti Malhotra (ORCID: https://orcid.org/0000-0001-8586-0234)
- Richard E. Cutler
- Tressa Hood (ORCID: https://orcid.org/0000-0001-8241-1572)
- Gregory M. Coté (ORCID: https://orcid.org/0000-0003-0181-886X)
Institutions
- City Of Hope National Medical Center (US)
- Harvard University (US)
- College of San Mateo (US)
- University of California, Irvine (US)
- University of Michigan (US)
- Keck Hospital of USC (US)
- Massachusetts General Hospital (US)
- USC Norris Comprehensive Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Deciphera Pharmaceuticals (United States) (US)
- Comprehensive Blood & Cancer Center (US)
- Center for Cancer Research (US)
- KRONOS (United States) (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0015
- Citations
- 2
- Primary Topic
- Salivary Gland Tumors Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Gateway for Cancer Research
- Gilead Sciences
- Adenoid Cystic Carcinoma Research Foundation
- Chordoma Foundation
- Merck KGaA
- MacroGenics
- Eisai
- Servier
- PharmaMar
- Genentech
- Daiichi Sankyo Europe